Institutional members access full text with Ovid®

Comparative Study of Helicobacter pylori Eradication Rates With 5-day Quadruple Concomitant Therapy and 7-day Standard Triple Therapy

Kim, Seung Young MD, PhD; Lee, Sang Woo MD, PhD; Hyun, Jong Jin MD; Jung, Sung Woo MD, PhD; Koo, Ja Seol MD, PhD; Yim, Hyung Joon MD, PhD; Park, Jong Jae MD, PhD; Chun, Hoon Jai MD, PhD; Choi, Jai Hyun MD, PhD

Journal of Clinical Gastroenterology: January 2013 - Volume 47 - Issue 1 - p 21–24
doi: 10.1097/MCG.0b013e3182548ad4
ALIMENTARY TRACT: Original Articles

Background: Several studies have shown the superiority of concomitant quadruple therapy containing 3 antibiotics over triple therapy for Helicobacter pylori infection. The aim of this study was to compare concomitant quadruple therapy with standard triple therapy for first-line H. pylori eradication.

Methods: A total of 270 patients with proven H. pylori infection were randomly assigned to one of 2 regimens: amoxicillin 1000 mg with clarithromycin 500 mg and lansoprazole 30 mg twice daily for 7 days (triple therapy) or amoxicillin 1000 mg with clarithromycin 500 mg, metronidazole 500 mg, and lansoprazole 30 mg twice daily for 5 days (concomitant therapy). The success of eradication was evaluated 4 to 5 weeks after completion of treatment.

Results: Eradication rates were 86.1% in the triple therapy and 91.4% in the concomitant therapy (per protocol), but the difference was not statistically significant. Mild adverse events were more frequently reported in the concomitant-therapy group (35.6%) than in the triple-therapy group (25.2%) (P=0.09).

Conclusions: Five-day quadruple concomitant therapy eradicated H. pylori in over 90% of patients. Accordingly, concomitant therapy is thought to be a promising alternative to triple therapy as a first-line treatment regimen for H. pylori eradication.

Department of Internal Medicine, Division of Gastroenterology and Hepatology, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, Korea

There have been no sources of support, including pharmaceutical and industry support.

The authors declare that they have nothing to disclose.

Reprints: Sang Woo Lee, MD, PhD, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Korea University Ansan Hospital, Korea University College of Medicine, 516 Gojan-dong, Danwon-gu, Ansan-si, Gyeonggi-do 425-707, Korea (e-mail: leesw@kumc.or.kr).

Received October 19, 2011

Accepted March 7, 2012

© 2013 Lippincott Williams & Wilkins, Inc.